It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Innate immune responses are linked to key metabolic pathways, yet the proximal signaling events that connect these systems remain poorly understood. Here we show that phosphofructokinase 1, liver type (PFKL), a rate-limiting enzyme of glycolysis, is phosphorylated at Ser775 in macrophages following several innate stimuli. This phosphorylation increases the catalytic activity of PFKL, as shown by biochemical assays and glycolysis monitoring in cells expressing phosphorylation-defective PFKL variants. Using a genetic mouse model in which PFKL Ser775 phosphorylation cannot take place, we observe that upon activation, glycolysis in macrophages is lower than in the same cell population of wild-type animals. Consistent with their higher glycolytic activity, wild-type cells have higher levels of HIF1α and IL-1β than PfklS775A/S775A after LPS treatment. In an in vivo inflammation model, PfklS775A/S775A mice show reduced levels of MCP-1 and IL-1β. Our study thus identifies a molecular link between innate immune activation and early induction of glycolysis.
Pro-inflammatory signals trigger innate immune pathways with consequential metabolic remodeling. Here authors show that a rate-limiting enzymes of glycolysis, PFKL, is directly regulated by innate stimuli via phosphorylation at Ser775, which modification in turn influences pro-inflammatory cytokine production.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Ludwig-Maximilians-Universität München, Gene Center and Department of Biochemistry, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 Ludwig-Maximilians-Universität München, Faculty of Biology, Human Biology and BioImaging, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
3 Technische Universität München, TranslaTUM, Center of Translational Cancer Research, Munich, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966); Technische Universität München, Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Munich, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966)
4 Cardiovascular Physiology and Pathophysiology, Ludwig-Maximilians-Universität München, Faculty of Medicine Biomedical Center, Planegg-Martinsried, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
5 Biotechnology and Bioinformatics, Technische Universität Braunschweig, Institute for Biochemistry, Braunschweig, Germany (GRID:grid.6738.a) (ISNI:0000 0001 1090 0254)
6 Helmholtz Zentrum München, Institute of Developmental Genetics, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525); Technische Universität München, TUM School of Life Sciences, Freising-Weihenstephan, Germany (GRID:grid.6936.a) (ISNI:0000 0001 2322 2966); German Center for Neurodegenerative Diseases (DZNE) site Munich, Munich, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3)